Here, in the context of treated HIV infection, pre-TLR9 agonist therapy CD169 levels were relatively low and there was a robust and temporally-associated increase CD169 expression which strongly supports our tested hypothesis. The gene discussed is SIGLEC1; the disease is HIV infectious disease.